S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(1.45%) $922.85
USD/EUR
(0.13%) $0.928
USD/NOK
(0.15%) $10.86
USD/GBP
(-0.02%) $0.792
USD/RUB
(-0.03%) $92.55

Realtime updates for ADC Therapeutics SA [ADCT]

Exchange: NYSE Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 16:00

6.90% $ 4.49

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for ADC Therapeutics SA

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors...

Stats
Today's Volume 977 894
Average Volume 819 944
Market Cap 370.56M
EPS $0 ( 2024-03-13 )
Next earnings date ( $-0.580 ) 2024-05-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -1.530
ATR14 $0.0160 (0.36%)
Insider Trading
Date Person Action Amount type
2024-01-03 Redmile Group, Llc Sell 59 986 Cash-settled Swaps
2024-02-01 Redmile Group, Llc Sell 19 700 Cash-settled Swaps
2024-02-01 Redmile Group, Llc Buy 205 483 Cash-settled Swaps
2024-01-31 Redmile Group, Llc Buy 150 000 Cash-settled Swaps
2024-01-29 Redmile Group, Llc Buy 150 000 Cash-settled Swaps
INSIDER POWER
-45.72
Last 79 transactions
Buy: 1 817 492 | Sell: 5 217 316

Volume Correlation

Long: -0.11 (neutral)
Short: 0.04 (neutral)
Signal:(49.537) Neutral

ADC Therapeutics SA Correlation

10 Most Positive Correlations
K0.945
NKX0.942
OGN0.941
JWN0.941
SPCE0.937
ZME0.936
BIG0.933
BBWI0.933
GSL0.933
USPH0.931
10 Most Negative Correlations
FLRT-0.949
SLB-0.944
CANE-0.944
OII-0.943
IEZ-0.94
OIH-0.937
WHD-0.937
HAL-0.935
AFT-0.934
BKR-0.933

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ADC Therapeutics SA Correlation - Currency/Commodity

The country flag 0.07
( neutral )
The country flag 0.02
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.54
( weak )
The country flag 0.10
( neutral )

ADC Therapeutics SA Financials

Annual 2023
Revenue: $69.56M
Gross Profit: $67.03M (96.36 %)
EPS: $-2.94
Q4 2023
Revenue: $16.79M
Gross Profit: $15.58M (92.76 %)
EPS: $-1.030
Q3 2023
Revenue: $14.49M
Gross Profit: $14.13M (97.47 %)
EPS: $-0.580
Q2 2023
Revenue: $19.28M
Gross Profit: $17.96M (93.16 %)
EPS: $-0.580

Financial Reports:

No articles found.

ADC Therapeutics SA

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators